Michal M. Hoppe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michal M. Hoppe has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Anand Devaprasath Jeyasekharan
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
1 shared publication - Anna S. Sedukhina
St. Marianna University
1 shared publication - Anthony Nicholas Karnezis
Department of Pathology and Laboratory Medicine, University of California, Davis, CA 95817, USA
1 shared publication - Brendan Nk Pang
National University of Singapore
1 shared publication - David G. Huntsman
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
1 shared publication - David Shao Peng Tan
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
1 shared publication
Latest Publications
- Open Access
Primary platinum resistance and immune exclusion in ovarian carcinomas with high expression of the homologous recombination mediator RAD51
Background: Homologous recombination deficiency (HRD) in ovarian cancer confers increased sensitivity to Poly-ADP-Ribose-Polymerase (PARP) inhibitors and platinum. The homologous recombination (HR) mediator RAD51, however, is commonly overexpressed, potentially driving unregulated HR. Due to non-quantitative measurements and heterogeneous cohorts, the clinical relevance of RAD51 expression in ovarian cancer is unclear. Methods: Fluorescent immunohistochemistry and multispectral imaging were used to quantitate RAD51 expression, in relation to other markers, in independent cohorts of ovarian carcinomas from British Columbia Cancer (BCC n =284) and the phase III SCOTROC4 trial ( n =268). Independent cohorts (TCGA n =566, GSE9891 n =267, GSE26712 n =185 and GSE3149 n =146) were used for mRNA expression and immune infiltration analyses. Results: RAD51-High tumours had shorter progression-free and overall survival compared to RAD51-Low cases in both BCC and SCOTROC4. The negative prognostic significance of high RAD51 was primarily evident in cases classified “HRD negative” by the Myriad genomic scar assay. Unexpectedly, overexpression of RAD51 in ovarian cancer cell lines did not affect sensitivity to platinum or PARP inhibitors, but modified the expression of immune-regulatory genes. Accordingly, tumours with high RAD51 mRNA showed consistent changes in immunomodulatory transcripts across four independent ovarian cancer cohorts. In-situ multiplexed imaging confirmed that high RAD51 tumours correlated with tumour exclusion of cytotoxic-T-cells, possibly explaining their poor outcomes after chemotherapy. Conclusions: High RAD51 expression, in conjunction with a HRD score nd line maintenance treatment of ovarian cancer. Our findings suggest that HRD negative ovarian tumours may be further stratified by RAD51 expression status in the context of platinum sensitivity, and may serve to guide future trials of HRD targeted agents.
Open AccessPrimary platinum resistance and immune exclusion in ovarian carcinomas with high expression of the homologous recombination mediator RAD51
Background: Homologous recombination deficiency (HRD) in ovarian cancer confers increased sensitivity to Poly-ADP-Ribose-Polymerase (PARP) inhibitors and platinum. The homologous recombination (HR) mediator RAD51, however, is commonly overexpressed, potentially driving unregulated HR. Due to non-quantitative measurements and heterogeneous cohorts, the clinical relevance of RAD51 expression in ovarian cancer is unclear. Methods: Fluorescent immunohistochemistry and multispectral imaging were used to quantitate RAD51 expression, in relation to other markers, in independent cohorts of ovarian carcinomas from British Columbia Cancer (BCC n =284) and the phase III SCOTROC4 trial ( n =268). Independent cohorts (TCGA n =566, GSE9891 n =267, GSE26712 n =185 and GSE3149 n =146) were used for mRNA expression and immune infiltration analyses. Results: RAD51-High tumours had shorter progression-free and overall survival compared to RAD51-Low cases in both BCC and SCOTROC4. The negative prognostic significance of high RAD51 was primarily evident in cases classified “HRD negative” by the Myriad genomic scar assay. Unexpectedly, overexpression of RAD51 in ovarian cancer cell lines did not affect sensitivity to platinum or PARP inhibitors, but modified the expression of immune-regulatory genes. Accordingly, tumours with high RAD51 mRNA showed consistent changes in immunomodulatory transcripts across four independent ovarian cancer cohorts. In-situ multiplexed imaging confirmed that high RAD51 tumours correlated with tumour exclusion of cytotoxic-T-cells, possibly explaining their poor outcomes after chemotherapy. Conclusions: High RAD51 expression, in conjunction with a HRD score nd line maintenance treatment of ovarian cancer. Our findings suggest that HRD negative ovarian tumours may be further stratified by RAD51 expression status in the context of platinum sensitivity, and may serve to guide future trials of HRD targeted agents.